ENHERTU Business Briefing

from the beginning

1. ENHERTU Business Briefing (1)

@

5-Year Business Plan (FY2021 FY2025) for Sustainable Growth

Strategic Pillars for the 5-Year Business Plan (FY2021 FY2025)

Oncology Revenue Target

ENHERTU : Clinical Development Plan | Breast cancer

ENHERTU : Clinical Development Plan | Gastric cancer & NSCLC

ENHERTU : Clinical Development Plan | CRC & other tumors

Primary Endpoint: PFS by BICR

Creation of Oncology Business Unit

2. ENHERTU Business Briefing (2)

Daiichi Sankyo OBU Global Leadership

Daiichi Sankyo OBU Global Leadership Team

Daiichi Sankyo's Transformation into Global Oncology Leader

ENHERTU : Roadmap to Transforming HER2 Targetable Cancers

ENHERTU : Solid Performance Globally

ESMO 2021: Defining Moment for Daiichi Sankyo's Transformation into Global Oncology Leader

ENHERTU : New Standard of Care for 2L mBC

ENHERTU : Historical Unprecedented Efficacy In Breast Cancer

ENHERTU : Media Reaction to DESTINY Breast03

ENHERTU : KEE Reaction to DESTINY Breast03

@

ENHERTU : Opportunity to Displace T DM1 in mBC

ENHERTU Next: Transform Treatment Landscape for Previously “Un targetable

ENHERTU : DESTINY Breast04 and DESTINY Breast06

ENHERTU : Clinical Development Program Highlights

Dato DXd: Potentially Best in Class TROP2 Directed ADC in NSCLC and Breast Cancer

HER3 DXd: First in Class HER3 Directed ADC in NSCLC and Breast Cancer

ENHERTU , Dato DXd & HER3 DXd: Lung Cancer Clinical Development Highlights

By 2030 DS will be a Global Innovator, ADC Leader Across Multiple Tumor Types with a Competitive Advantage in Oncology

@

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6